

Appendix of the research article entitled:

Psoriatic skin inflammation is promoted by c-Jun/AP-1 dependent CCL2 and IL-23 expression in Dendritic cells

Novoszel et al.

Table of contents:

Appendix Figure S1. Kinetic of keratinocyte differentiation and proliferation in IMQ-treated c-Jun^{Δ/Δ}CD11c-Cre mice

Appendix Figure S2. CCL2 is dispensable for IMQ-induced skin inflammation

Appendix Figure S3. AP-1 inhibition reduces CCL2 and IL-23 expression in IMQ-stimulated BMDCs

Appendix Figure S4. IL-23 is dispensable for pDC stimulation and migration to skin

Appendix Figure S5. c-Jun/AP-1 controls CCL-2 and IL-23 expression in BMDCs stimulated with the Adenine analogs and TLR7 ligands CL264 and CL307.

Appendix Figure S6. Expression analysis of cutaneous immune cells in steady-state.

Appendix Figure S7. Gating strategy for cutaneous immune cell populations

Appendix Figures

Appendix Methods

Appendix Table S1. Antibodies

Appendix Table S2. Primers

Appendix Table S3. List of *P*-values

Appendix Figure Legends

Appendix Figure S1. Kinetic of keratinocyte differentiation and proliferation in IMQ-treated *c-Jun^{Δ/Δ}CD11c-Cre* mice

- A. Immunofluorescence of K5 (red), K10 (green) and DAPI in back skin from *c-Jun^{fl/fl}* and *c-Jun^{Δ/Δ}CD11c-Cre* mice treated daily with IMQ for 36, 48 and 72h. Scale bar: 100 μm, Magnification 20x.
- B. Immunofluorescence of Ki67 (green) and DAPI in back skin from *c-Jun^{fl/fl}* and *c-Jun^{Δ/Δ}CD11c-Cre* mice treated daily with IMQ for 36, 48 and 72h. Scale bar: 100 μm, Magnification 20x.

Appendix Figure S2. CCL2 is dispensable for IMQ-induced skin inflammation

- A. Hematoxylin and eosin stained sections of mouse back skin from wild-type and *Ccl2^{-/-}* mice treated with IMQ for 3 and 5 days. Bright-field images, Magnification: 20x, Scale bar: 100 μm.
- B. Epidermal thickness of the back skin was analyzed at the indicated time points in *Ccl2^{-/-}* mice. (*n* = 3-21; 2 independent experiments).
- C. Trans-epidermal water loss (TEWL) was analyzed in the back skin of wild-type and *Ccl2^{-/-}* mice at the indicated time-points. (*n* = 3-9; 2 independent experiments).
- D. Flow cytometric analysis of the immune infiltrate in back skin of wild-type and *Ccl2^{-/-}* mice. Numbers next to gates give the percentage of indicated immune cells among percentage of live, single, CD45⁺ cells. Plots shown are pre-gated on live, single, CD45⁺ cells.
- E. Quantification of immune cell populations as defined in (D). Results are given as percentage of live, single cells. (*n* = 6; 2 independent experiments).

Data information: Data are shown as mean ± SEM. *P*-values were calculated by unpaired, two-tailed *t*-test (E) or one-way (B) or two-way ANOVA with Tukey multiple comparison test (C). Statistical significance: ns > 0.05, **P* < 0.05, ***P* < 0.01. See Appendix Table S3 for exact *P*-values.

Appendix Figure S3. AP-1 inhibition reduces CCL2 and IL-23 expression in IMQ-stimulated BMDCs

- A. BMDCs were generated from *Tlr7*^{-/-}, *c-Jun*^{fl/fl} and *c-Jun*^{Δ/Δ} *Mx1*-Cre BM, pre-treated with the AP-1 inhibitor T-5224 (20 μM, 1h) and/or stimulated with IMQ for 16h. Mean fluorescence intensity (MFI) of BMDC-CD80 was analyzed by flow cytometry.
- (*n* = 2-3, 2 independent experiments performed (*n* = 2-6), one representative shown).
- B. BMDCs were generated and analyzed for CD86 expression as described in (A).
- C. BMDCs generated from *Tlr7*^{-/-}, *c-Jun*^{fl/fl} or *c-Jun*^{Δ/Δ} *Mx1*-Cre BM, were pre-treated with the AP-1 inhibitor T-5224 (20 μM, 1h) and/or stimulated with IMQ for 16h. CCL2 protein was quantified in supernatants by ELISA. (*n* = 2-6; 2 independent experiments).
- D. BMDCs were generated as described in (C). 1x10⁵ BMDCs were plated, pre-treated with the AP-1 inhibitor T-5224 (20 μM, 1h) and analyzed for IL-23 expression 4 h after stimulation with IMQ by ELISA.

Data information: Data are shown as mean ± SEM. *P*-values were calculated by one-way ANOVA with Tukey multiple comparison test (A-D). Statistical significance: ns > 0.05, **P* < 0.05, ***P* < 0.01, ****P* < 0.001, *****P* < 0.0001. See Appendix Table S3 for exact *P*-values.

Appendix Figure S4. IL-23 is dispensable for pDC stimulation and migration to skin

- A. Flow cytometry of back skin 12h after intradermal (i.d.) injection of rIL-23 (1 μg). Analyzed were pDCs (BST-2⁺B220⁺CD11c^{int}CD11b⁻). (*n* = 6; 2 independent experiment).
- B. qRT-PCR detection of *Ccl2* and *Il17a* mRNA expression levels in total back skin of wild-type mice after i.d. injection of rIL-23 (1 μg; 6, 12 and 36h). (*n* = 4-11; 2 independent experiments).
- C. qRT-PCR detection of *Il-12rb1*, *Il-12rb2* and *Il-23r* mRNA expression levels in FACS sort purified (B220⁺CD11c⁺CD11b⁻; purity > 90%) BM-pDCs stimulated with IMQ for 8h. (*n* = 3; 3 independent experiments).

- D. BM-pDCs were stimulated with rIL-12 (100 ng) or rIL-23 (100 ng) and/or IMQ for 8h. qRT-PCR detection was performed for *Gzmb*, *Trail* and *Ifng* mRNA. ($n=4-9$; 3-4 independent experiments).

Data information: Data are shown as mean $\pm$ SEM. *P*-values were calculated by unpaired, two-tailed *t*-test (A, C and D) or one-way ANOVA with Dunnett's multiple comparison test (B). $ns > 0.05$, $*P < 0.05$, $**P < 0.01$, $**** P < 0.0001$. See Appendix Table S3 for exact *P*-values.

Appendix Figure S5. c-Jun/AP-1 controls CCL-2 and IL-23 expression in BMDCs stimulated with the Adenine analogs and TLR7 ligands CL264 and CL307.

- A. BMDCs were generated from *Tlr7*^{-/-}, *c-Jun*^{fl/fl} and *c-Jun* ^{Δ/Δ} *Mx1*-Cre BM and stimulated with CL264 or CL307 for 16h. Mean fluorescence intensity (MFI) of CD80 was analyzed on BMDCs by flow cytometry. ($n = 2-3$, 2 independent experiments performed ($n = 4-6$), one representative shown).
- B. BMDCs were generated and analyzed for CD86 expression as described in (A). ($n = 3-4$, 2 independent experiments performed ($n = 4-6$), one representative shown).
- C. BMDCs were generated from BM of indicated genotype and stimulated with CL264 or CL307 for 16h. CCL2 protein was quantified in supernatant by ELISA. ($n=4-6$; 2 independent experiments).
- D. BMDCs were generated as described in (C). 1×10^5 BMDCs were plated and analyzed for IL-23 expression 4 h after stimulation with CL264 or CL307 by ELISA.

Data information: Data are shown as mean $\pm$ SEM. *P*-values were calculated by one-way ANOVA with Tukey multiple comparison posttest (A-D). $ns > 0.05$, $*P < 0.05$, $**P < 0.01$, $*** P < 0.001$, $**** P < 0.0001$. See Appendix Table S3 for exact *P*-values.

Appendix Figure S6. Expression analysis of cutaneous immune cells in steady-state.

- A. qRT-PCR detection of *c-Jun*, *Ccl2* and *Il23p19* in indicated cell populations sorted from untreated back skin as described in Figure 4B. Fold change is shown relative to cDC1. (10 mice were pooled, 1 experiment).

- B. qRT-PCR detection of *Il23p19* in granulocytes (Gr-1⁺), non-immune cells (CD45⁻) and T cells (CD3ε⁺) sorted from untreated back skin as described in EV Figure 2E. (*n* = 4-5; 2 independent experiments).


Data information: Data are shown as mean ± SEM. *P*-values were calculated by one-way ANOVA with Tukey multiple comparison posttest (B). ns > 0.05, **P* < 0.05, ***P* < 0.01. See Appendix Table S3 for exact *P*-values.

Appendix Figure S7. Gating strategy for cutaneous immune cell populations


- A. Gating strategy for flow cytometric analysis of immune cells in mouse back skin. In all experiments cell debris was discarded (FCS/SSC) and single events (SSC-A/SSC-W) were selected. Live cells (7-AAD) were gated on immune cells (CD45⁺) before further analysis. Shown is a staining panel to identify dendritic cells (CD45⁺CD11c⁺MHCII⁺CD64⁻Ly6-C/G⁻) negative (DC1) or positive (DC2) for CD11b, Macrophages (CD45⁺CD11b⁺CD64⁺) negative (Mac1) or positive for MHCII (Mac2), Monocytes (CD45⁺CD11b⁺CD64⁻Ly6C^{hi}), neutrophils (CD45⁺CD11b⁺CD64⁻Ly6G⁺), γδ T cells (CD45⁺, CD11b⁻, γδ TCR^{int}, CD3ε^{int}) and dendritic epidermal T cells (CD45⁺, CD11b⁻, γδ TCR⁺, CD3ε⁺). Ly6C⁺ cells encompass CD45⁺CD11b⁻Ly6C⁺ and CD11b⁺ cells are CD11b⁺, but negative for CD64, Ly6C and Ly6G. Color indicates overlap of cell population with populations defined by t-SNE in B.
- B. t-SNE analysis was performed on a flow cytometry staining panel as described in A. Color in t-SNE plot on the left shows overlap with populations gated by conventional flow cytometry above. On the right a legend gives a label to the populations defined by t-SNE.
- C. Protein quantification of CCL2, CXCL1, TNF-α, TSLP, IL-17A, IL-18 and IL-33 by Luminex multiplex assay in cutaneous lysates of vehicle or JNK inhibitor treated *c-Jun*^{fl/fl} mice after 5 days of IMQ treatment on the back skin. (*n* = 3 for untreated group, 1 independent experiment and *n* = 6 for IMQ treated group, 2 independent experiments).

Data information: Data are shown as mean $\pm$ SEM. *P*-values were calculated by one-way ANOVA with Tukey multiple comparison test (C). ns > 0.05, **P* < 0.05, ***P* < 0.01, *****P* < 0.0001. See Appendix Table S3 for exact *P*-values.

Appendix Figure S1




Appendix Figure S2




Appendix Figure S3


A




B




C




D



Appendix Figure S4




Appendix Figure S5




Appendix Figure S6

A




B




Appendix Figure S7


A



B



C



Appendix Methods

Preparation of cutaneous cell suspensions

To prepare a single cell suspension back skin was minced and digested in a mix containing PBS, 3% FCS (PAA), 100 µg/mL DNase I (Sigma-Aldrich) and 100 µg/mL LiberaseTM (Roche) for 1h at 37°C. Enzymatically digested skin was washed and filtered through 70 µm cell strainers (BD Biosciences) before analysis.

For intracellular staining of IL-17A a single cell suspension was prepared from ears. Here, ears were separated in a dorsal and ventral side, minced and digested as described above.

Histological analysis

Skin tissue biopsies were fixed in formalin and embedded in paraffin. 5 µm sections were cut before sections were deparaffinized in xylene and rehydrated by ethanol (2 x 100 and 2 x 70 %). Sections were stained with hematoxylin and eosin (H&E) according to standard procedures. Epidermal thickness was determined as the length between basement membrane and stratum corneum. For each H&E stained section 3 pictures (20x, random position) were taken and for each picture epidermal thickness (4x measurement points) and epidermal layers was quantified using ImageJ.

Immunofluorescence of mouse tissue

For immunofluorescence of formalin-fixed murine back skin antigen retrieval (Citrate buffer pH =6, DAKO) was performed on deparaffinized skin sections. Sections were blocked with 5 % horse serum, 2 % bovine serum albumin (BSA) in phosphate-buffered saline (PBS) (blocking buffer) for 1 hour (room temperature). An overnight incubation at 4 °C with the primary antibodies (AB) diluted in blocking buffer followed. A washing step (3 x PBS, 5 min) and labelling with the appropriate secondary antibodies was done next (1h, dark humidified chamber). A counterstain with DAPI was performed. For immunofluorescence of frozen tissue, back skin was embedded in OCT (Sakura), followed by an acetone fixation (20 min, 4 °C). Lastly, for immunofluorescence of cell culture suspensions fixation in 4 % paraformaldehyde for 20 minutes was done. After fixation cells were smeared on poly-L-Lysine coated glass slides. Blocking and staining with primary and secondary AB followed as described above.

Primary AB used are listed in Appendix Table S1 and their fixation method is indicated. Images were recorded on a Nikon Eclipse 80i microscope.

Western blot

Western blot was done as previously described (Lichtenberger et al, 2010) with antibodies listed in Appendix Table S1. Western blots were automatically recorded with a ChemiDoc Touch Imaging System (Biorad).

Appendix Table S1. Antibodies

Reagent	Source	Identifier	Clone	Dilution
<i>Flow cytometry antibodies</i>				
B220	BioLegend	APC, PE-Cy7, BV650	RA3-6B2	¼ µg/10 ⁶ cells
BST-2	BioLegend	PE	129C1	¼ µg/10 ⁶ cells
BST-2	ThermoFisher	PE	eBio129c	¼ µg/10 ⁶ cells
CD-3ε	BioLegend	Pe-Cy7	145-2C11	¼ µg/10 ⁶ cells
CD11b	BioLegend	AF488, Pb, PE-Cy7	M1/70	¼ µg/10 ⁶ cells
CD11c	BioLegend	AF488, APC, BV605	N418	¼ µg/10 ⁶ cells
CD19	BioLegend	AF700	6D5	¼ µg/10 ⁶ cells
CD45	BioLegend	PE, APC, APC-Cy7, AF700, BV 510	30-F11	¼ µg/10 ⁶ cells
CD64	BioLegend	PE	X54-5/7.1	¼ µg/10 ⁶ cells
CD80	BioLegend	PE	16-10A1	¼ µg/10 ⁶ cells
CD86	BioLegend	APC-Cy7	GL-1	¼ µg/10 ⁶ cells
CD103	BD Pharmingen	PE	M290	¼ µg/10 ⁶ cells
CD172a	BioLegend	PE-Cy7	P84	¼ µg/10 ⁶ cells
CD207	BioLegend	APC	4C7	¼ µg/10 ⁶ cells
Gr-1	BioLegend	Pb	RB6-8C5	¼ µg/10 ⁶ cells
Ly6C	BD Pharmingen	FITC	AL-21	¼ µg/10 ⁶ cells
Ly6C	BioLegend	Pb, PE-Cy7, BV510	HK1.4	¼ µg/10 ⁶ cells
Ly6G	BioLegend	Pb, APC-Cy7, AF700	1A8	¼ µg/10 ⁶ cells
MHC-II	BioLegend	PE-Cy7, APC-Cy7	M5/114.15.2	¼ µg/10 ⁶ cells
NK1.1	BioLegend	AF700	PK136	¼ µg/10 ⁶ cells
TCRβ	BioLegend	AF700	H57-597	¼ µg/10 ⁶ cells
XCR1	BioLegend	APC	ZET	¼ µg/10 ⁶ cells
γδ TCR	BioLegend	FITC, APC	GL3	¼ µg/10 ⁶ cells
<i>Human FC antibodies</i>				
CD1a	BD Biosciences	Pb	HI149	¼ µg/10 ⁶ cells
CD80	BD Biosciences	Qdot 605	L307.4	¼ µg/10 ⁶ cells
CD86	BD Biosciences	Pe-Cy7	2331	¼ µg/10 ⁶ cells
<i>Intracellular FC antibodies</i>				
IL-17A	BioLegend	PE	TC11-18H10.1	¼ µg/10 ⁶ cells
PE Rat IgG1, κ Isotype Ctrl	BioLegend	PE	RTK 207-1	¼ µg/10 ⁶ cells
IL-23p19	ThermoFisher	efluor660	fc23cpg	¼ µg/10 ⁶ cells
Rat IgG1, κ Isotype Ctrl, eFluor 660	ThermoFisher	efluor660	eBRG1	¼ µg/10 ⁶ cells
IL-12p40	BioLegend	PE	C15.6	¼ µg/10 ⁶ cells

<i>Immunofluorescence (IF on Paraffin (P) or frozen (F) tissue and cell culture suspensions (S))</i>				
K5 (IF-P)	Progen	GP-CK5	guinea pig polyclonal	1:100
K10 (IF-P)	BioLegend	905401	Poly19054	1:100
Ki-67 (IF-P)	Abcam	ab15580	Rabbit polyclonal	1:100
c-Jun (IF-P)	Cell Signaling	9165	60A8	1:100
CD11c (IF-F IF-S)	BioLegend	117311	N418	1:400
IL23p19 (IF-S)	Abcam	45420	Rabbit polyclonal	1:100
CD11c (Human) (IF-F)	BD Biosciences	550375	B-ly6	1:50
CCL2 (Human) (IF-F)	Sigma-Aldrich	HPA019163-100UL	HPA019163	1:100
IL23p19 (Human) (IF-F)	Sigma Aldrich	HPA001554- 100UL	HPA001554	1:100
c-Jun (Human) (IF-F)	Biotechne	AF2670	Sheep polyclonal	1:50
CD1a (Human) (IF-P)	Novus biologicals	NBP2-34313	O10	1:50
CD1c (Human) (IF-P IF-F)	Novus biologicals	NB100-65313	L161	1:100
CD14 (Human) ((IF-P IF-F)	BioLegend	325603	HCD14	1:100

<i>Chromatin Immunoprecipitation</i>				
c-Jun	Cell Signaling	9165	60A8	1:50

<i>Western Blot</i>				
c-Jun	Cell Signaling	9165	60A8	1:1000
P-c-Jun	Cell Signaling	3270	D47G9	1:1000
JNK/SAPK	Cell Signaling	9252	-	1:1000
P-JNK/P-SAPK	Cell Signaling	9255	G9	1:1000
Vinculin	Sigma Aldrich	V9131	hVIN-1	1:500

Appendix Table S2. Primers

Primer name	Forward primer (5'-3')	Reverse primer (5'-3')
<i>c-Jun</i>	AAAACCTTGAAAGCGCAAAA	CGCAACCAGTCAAGTTCTCA
<i>c-Fos</i>	CAGCCTTTCTACTACCATTC	ACAGATCTGCGCAAAAGTCC
<i>Ccl2</i>	GAAGGAATGGGTCCAGACAT	ACGGGTCAACTTCACATTCA
<i>Ccl20</i>	CGACTGTTGCCTCTCGTACA	GAGGAGGTTACAGCCCTTT
<i>Cxcl1</i>	GCCTATCGCCAATGAGCTG	ATTCTTGAGTGTGGCTATGA
<i>Fosb</i>	GTTGCGCAGAGAGCGGAAC	GCCTTTTCTCTTCAAGCTG
<i>Fra-1</i>	GCATGTACCGAGACTACGGG	AGGTGGAACCTCTGCTGCTG
<i>Fra-2</i>	ACGCCGAGTCCTACTCCAG	CAGGCATATCTACCCGGAAC
<i>Gzmb</i>	ATTCCCCACCCAGACTATAATCC	TTACTCTTCAGCTTTAGCAGCATGA
<i>Il1b</i>	GGGCCTCAAAGGAAAGAATC	TACCAGTTGGGGAACCTCTGC
<i>Il6</i>	GAGGATACCACTCCCAACAGACC	AAGTGCATCATCGTTGTTCATACA
<i>Il12rb1</i>	ACTGGAATGTGTCTGAAG	CGTATCTGGATCTCTTGG
<i>Il12rb2</i>	CCTCAATGGTATAGCAGAAC	TAGCCTTGGAATCCTTGG
<i>Il17a</i>	GCTCCAGAAGGCCCTCAGA	CTTCCCTCCGCATTGACA
<i>Il22</i>	TTTCTTGACCAAACTCAGCA	CTGGATGTTCTGGTCGTCAC
<i>Il23p19</i>	ACCAGCGGGACATATGAATCTA	GAAGTGGCTGTTGTCCTTGA
<i>Il23r</i>	GCTCGGATTTGGTATAAAGG	ACTTGGTATCTATGTAGGTAGG
<i>Ifng</i>	CTGAGACAATGAACGCTACAC	TCCACATCTATGCCACTTGAG
<i>Junb</i>	ATGTGCACGAAAATGGAACA	CCTGACCCGAAAAGTAGCTG
<i>S100a8</i>	TTCGTGACAATGCCGTCTGA	AGGGCATGGTGATTTCTTGT
<i>S100a9</i>	AGATGGCCAACAAAGCACCT	TCTCTTTCTTCATAAAGGTTGCCA
<i>Tbp</i>	GGGGAGCTGTGATGTGAAGT	CCAGGAAATAATTCTGGCTCAT
<i>Tnfa</i>	CTGAACTTCGGGGTGATCGG	GGCTTGCTCACTCGAATTTTGAGA
<i>Trail</i>	GTGTCTGTGGCTGTGACTTACA	AATGCCCTTTCCGAGAGGA
Promoter		
<i>c-Jun (CHIP)</i>	CTCTAGCCACAACAACCTCA	TTCACACTAGCAGGTGACTC
<i>mut1(Luciferase Assay)</i>	TCCCACCTGCTCTGAGCCA CCTGCTAGTGTGAAG	TTCCCCTCCCTACATCA TCTCCCTCTTTGGAGAG
<i>mut2 (Luciferase assay)</i>	GGGGAATCCCACCTGCTC ATAGTCA CCTGCTAGTGTGA	TCCCTACATCATCTCCCTCTTT GGAGAGCCCAGGTATG

Appendix Table S3. List of *P* -values

Figure 1

Figure 1 A		
Tukey's multiple comparisons test	Summary	Adjusted P Value
<i>c-Jun</i> ^{fl/fl} - 1.5 days vs <i>c-Jun</i> ^{Δ/Δ} <i>Mx1</i> -Cre - 1.5 days	*	0.0218
<i>c-Jun</i> ^{fl/fl} - 3 days vs <i>c-Jun</i> ^{Δ/Δ} <i>Mx1</i> -Cre - 3 days	***	0.0007
Figure 1B		
Tukey's multiple comparisons test	Summary	Adjusted P Value
<i>c-Jun</i> ^{fl/fl} - 1.5 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c</i> -Cre - 1.5 days	***	0.0006
<i>c-Jun</i> ^{fl/fl} - 3 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c</i> -Cre - 3 days	****	<0,0001
Figure 1C		
Tukey's multiple comparisons test	Summary	Adjusted P Value
<i>c-Jun</i> ^{fl/fl} - 1.5 days vs <i>c-Jun</i> ^{Δ/Δ} <i>K5</i> -Cre-ER ^{T2} - 1.5 days	ns	>0,9999
<i>c-Jun</i> ^{fl/fl} - 3 days vs <i>c-Jun</i> ^{Δ/Δ} <i>K5</i> -Cre-ER ^{T2} -Cre - 3 days	ns	0.9972
Figure 1 E LEFT		
Tukey's multiple comparisons test	Summary	Adjusted P Value
<i>c-Jun</i> ^{fl/fl} - 2 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c</i> -Cre - 2 days	*	0.018
<i>c-Jun</i> ^{fl/fl} - 3 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c</i> -Cre - 3 days	****	<0,0001
<i>c-Jun</i> ^{fl/fl} - 5 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c</i> -Cre - 5 days	****	<0,0001
Figure 1 E RIGHT		
Tukey's multiple comparisons test	Summary	Adjusted P Value
<i>c-Jun</i> ^{fl/fl} - 2 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c</i> -Cre - 2 days	****	<0,0001

<i>c-Jun</i> ^{fl/fl} - 3 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c</i> -Cre - 3 days	****	<0,0001
<i>c-Jun</i> ^{fl/fl} - 5 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c</i> -Cre - 5 days	****	<0,0001
Figure 1 F		
Bonferroni's multiple comparisons test*	Summary	Adjusted P Value
<i>c-Jun</i> ^{fl/fl} - 0 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c</i> -Cre - 0 days	ns	>0,9999
<i>c-Jun</i> ^{fl/fl} - 0 days vs <i>c-Jun</i> ^{fl/fl} - 2 days	ns	0.8893
<i>c-Jun</i> ^{fl/fl} - 0 days vs <i>c-Jun</i> ^{fl/fl} - 3 days	***	0.0002
<i>c-Jun</i> ^{fl/fl} - 0 days vs <i>c-Jun</i> ^{fl/fl} - 5 days	****	<0,0001
<i>c-Jun</i> ^{fl/fl} - 2 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c</i> -Cre - 2 days	ns	>0,9999
<i>c-Jun</i> ^{fl/fl} - 3 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c</i> -Cre - 3 days	**	0.0011
<i>c-Jun</i> ^{fl/fl} - 5 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c</i> -Cre - 5 days	*	0.038
Figure 1 G		
Bonferroni's multiple comparisons test*	Summary	Adjusted P Value
<i>c-Jun</i> ^{fl/fl} - 0 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c</i> -Cre - 0 days	ns	>0,9999
<i>c-Jun</i> ^{fl/fl} - 0 days vs <i>c-Jun</i> ^{fl/fl} - 2 days	*	0.0288
<i>c-Jun</i> ^{fl/fl} - 0 days vs <i>c-Jun</i> ^{fl/fl} - 3 days	****	<0,0001
<i>c-Jun</i> ^{fl/fl} - 0 days vs <i>c-Jun</i> ^{fl/fl} - 5 days	****	<0,0001
<i>c-Jun</i> ^{fl/fl} - 2 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c</i> -Cre - 2 days	ns	0.7809
<i>c-Jun</i> ^{fl/fl} - 3 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c</i> -Cre - 3 days	****	<0,0001
<i>c-Jun</i> ^{fl/fl} - 5 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c</i> -Cre - 5 days	*	0.0107

Figure 1 H		
Bonferroni's multiple comparisons test*	Summary	Adjusted P Value
<i>c-Jun</i> ^{fl/fl} - 0 days vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - 0 days	ns	>0,9999
<i>c-Jun</i> ^{fl/fl} - 0 days vs <i>c-Jun</i> ^{fl/fl} - 2 days	**	0.0024
<i>c-Jun</i> ^{fl/fl} - 0 days vs <i>c-Jun</i> ^{fl/fl} - 3 days	****	<0,0001
<i>c-Jun</i> ^{fl/fl} - 0 days vs <i>c-Jun</i> ^{fl/fl} - 5 days	****	<0,0001
<i>c-Jun</i> ^{fl/fl} - 2 days vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - 2 days	ns	0.8749
<i>c-Jun</i> ^{fl/fl} - 3 days vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - 3 days	ns	0.0624
<i>c-Jun</i> ^{fl/fl} - 5 days vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - 5 days	***	0.0006

Figure 2

Figure 2A		
Bonferroni's multiple comparisons test	Summary	Adjusted P Value
<i>c-Jun</i> ^{fl/fl} -0 days vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre- 0 days	ns	>0,9999
<i>c-Jun</i> ^{fl/fl} -0 days vs <i>c-Jun</i> ^{fl/fl} -0.5 days	****	<0,0001
<i>c-Jun</i> ^{fl/fl} -0 days vs <i>c-Jun</i> ^{fl/fl} -1.5 days	****	<0,0001
<i>c-Jun</i> ^{fl/fl} -0 days vs <i>c-Jun</i> ^{fl/fl} -3 days	ns	>0,9999
<i>c-Jun</i> ^{fl/fl} -0 days vs <i>c-Jun</i> ^{fl/fl} -5 days	ns	>0,9999
<i>c-Jun</i> ^{fl/fl} - 0.5 days vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - 0.5 days	****	<0,0001
<i>c-Jun</i> ^{fl/fl} - 1.5 days vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - 1.5 days	****	<0,0001
<i>c-Jun</i> ^{fl/fl} - 3 days vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - 3 days	ns	>0,9999
<i>c-Jun</i> ^{fl/fl} - 5 days vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - 5 days	ns	>0,9999

Figure 2C		
Multiple t-Test- Holm Sidak Method	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} - 0 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c-Cre</i> - 0 days	ns	0.7671
<i>c-Jun</i> ^{fl/fl} - 0.5 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c-Cre</i> - 0.5 days	*	0.0354
Figure 2D		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} - 0.5 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c-Cre</i> - 0.5 days	****	<0,0001
<i>c-Jun</i> ^{fl/fl} - 1.5 days vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c-Cre</i> - 1.5 days	*	0.0109
Figure 2E		
Kruskal-Wallis-Test*	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} - LAL vs <i>c-Jun</i> ^{fl/fl} - IMQ	**	0.0087
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c-Cre</i> - IMQ	***	0.0001
Figure 2F		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} - LAL vs <i>c-Jun</i> ^{fl/fl} - IMQ	*	0.0404
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} <i>CD11c-Cre</i> - IMQ	****	<0,0001
Figure 2G		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>Tlr7</i> ^{-/-} - IMQ	****	<0,0001
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{fl/fl} - IMQ- JNKi	****	<0,0001
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} <i>Mx1-Cre</i> - IMQ	****	<0,0001
Figure 2J - I		
Tukey's PBS vs rCCL2	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} - PBS vs <i>c-Jun</i> ^{fl/fl} - rCCL2	*	0.0454

<i>c-Jun</i> ^{fl/fl} - rCCL2 vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - rCCL2	ns	0.9246
Figure 2J - II		
Tukey's PBS vs IMQ	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} - PBS vs <i>c-Jun</i> ^{fl/fl} - IMQ	****	<0,0001
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - IMQ	**	0.0084
Figure 2J - III		
Tukey's IMQ vs IMQ + rCCL2	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} - PBS vs <i>c-Jun</i> ^{fl/fl} - IMQ + rCCL2	**	0.0033
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - IMQ + rCCL2	ns	0.8904

Figure 3

Figure 3A		
Unpaired t test with Welch's correction	Summary	<i>P</i> Value
<i>c-Jun</i> ^{fl/fl} - LAL vs <i>c-Jun</i> ^{fl/fl} - IMQ	*	0.0236
<i>JunB</i> ^{fl/fl} - LAL vs <i>JunB</i> ^{fl/fl} - IMQ	ns	0.1744
<i>Fra-1</i> ^{fl/fl} - LAL vs <i>Fra-1</i> ^{fl/fl} - IMQ	**	0.0023
<i>Fra-2</i> ^{fl/fl} - LAL vs <i>Fra-2</i> ^{fl/fl} - IMQ	**	0.0033
<i>FosB</i> ^{fl/fl} - LAL vs <i>FosB</i> ^{fl/fl} - IMQ	****	<0,0001
Unpaired t test	Summary	<i>P</i> Value
<i>c-Fos</i> ^{fl/fl} - LAL vs <i>c-Fos</i> ^{fl/fl} - IMQ	***	0.001
Figure 3B		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} - vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre	***	0.0003
<i>c-Jun</i> ^{fl/fl} - vs <i>c-Jun</i> ^{fl/fl} - IMQ	***	0.0005
<i>c-Jun</i> ^{fl/fl} -IMQ vs <i>c-Jun</i> ^{Δ/Δ} CD11c- Cre-IMQ	****	<0,0001

Figure 3C- <i>Il23p19</i>		
Unpaired t test with Welch's correction	Summary	P Value
c-Jun ^{fl/fl} -32h vs c-Jun ^{Δ/Δ} CD11c-Cre-32h	*	0.0195
c-Jun ^{fl/fl} -48h vs c-Jun ^{Δ/Δ} CD11c-Cre-48h	*	0.0109
Figure 3C- <i>Il17a</i>		
Unpaired t test with Welch's correction	Summary	P Value
c-Jun ^{fl/fl} -32h vs c-Jun ^{Δ/Δ} CD11c-Cre-32h	**	0.0096
c-Jun ^{fl/fl} -48h vs c-Jun ^{Δ/Δ} CD11c-Cre-48h	*	0.049
Figure 3D - IL-23		
Tukey's multiple comparisons test	Summary	Adjusted P Value
c-Jun ^{fl/fl} vs c-Jun ^{Δ/Δ} CD11c-Cre	ns	0.9875
c-Jun ^{fl/fl} -48h vs c-Jun ^{Δ/Δ} CD11c-Cre-48h	*	0.046
Figure 3D - IL-17A		
Kruskal-Wallis multiple comparison test	Summary	Adjusted P Value
c-Jun ^{fl/fl} vs c-Jun ^{Δ/Δ} CD11c-Cre	ns	>0,9999
c-Jun ^{fl/fl} -48h vs c-Jun ^{Δ/Δ} CD11c-Cre-48h	*	0.0414
Figure 3E		
Tukey's multiple comparisons test	Summary	Adjusted P Value
c-Jun ^{fl/fl} - IMQ vs <i>Tlr7</i> ^{-/-} - IMQ	****	<0,0001
c-Jun ^{fl/fl} - IMQ vs c-Jun ^{fl/fl} - IMQ- <i>JNKi</i>	***	0.0008
c-Jun ^{fl/fl} - IMQ vs c-Jun ^{Δ/Δ} <i>Mx1</i> -Cre - IMQ	*	0.0199
Figure 3F LEFT		
Tukey's multiple comparisons test	Summary	Adjusted P Value

<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} - IMQ	****	<0,0001
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} Mx1-Cre - IMQ	****	<0,0001
Figure 3F RIGHT		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} - IMQ	****	<0,0001
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} Mx1-Cre - IMQ	***	0.0005
Figure 3G		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} - IMQ	*	0.0267
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - IMQ	**	0.0056
Figure 3I		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{Δ/Δ} Mx1-Cre	ns	0.9792
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} - IMQ	***	0.0003
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} Mx1-Cre - IMQ	***	0.0001
Figure 3J		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
LAL vs IMQ	****	<0,0001
IMQ vs IMQ + JNKi	****	<0,0001
IMQ vs mut1-IMQ	****	<0,0001
IMQ vs mut2-IMQ	**	0.0042
Figure 3K		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} - IMQ	***	0.0006
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - IMQ	*	0.0143

Figure 3L		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} - IMQ	****	<0,0001
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} - IMQ + rIL-23	****	<0,0001
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} - rIL-23	***	0.0002
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - IMQ	****	<0,0001
<i>c-Jun</i> ^{fl/fl} - IMQ-IL-23 vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - IMQ-IL-23	ns	0.9294
<i>c-Jun</i> ^{fl/fl} - IL-23 vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - IL-23	ns	>0,9999

Figure 4

Figure 4C- cDC2 - c-Jun		
Unpaired t test with Welch's correction	Summary	<i>P</i> Value
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - IMQ	*	0.018
Figure 4C- cDC2 - Ccl2		
Unpaired t test	Summary	<i>P</i> Value
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - IMQ	*	0.0348
Figure 4C- cDC2 - Il23p19		
Unpaired t test with Welch's correction	Summary	<i>P</i> Value
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - IMQ	*	0.0359
Figure 4C- Mac - c-Jun		
Unpaired t test	Summary	<i>P</i> Value
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - IMQ	ns	0.2658
Figure 4C- Mac - Ccl2		
Unpaired t test with Welch's correction	Summary	<i>P</i> Value

<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - IMQ	ns	0.3438
Figure 4C- Mac - <i>Il23p19</i>		
Unpaired t test	Summary	<i>P</i> Value
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - IMQ	ns	0.7326
Figure 4E- Mac - <i>c-Jun</i>		
Unpaired t test	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - IMQ	ns	0.7346
Figure 4E- Mac - <i>Ccl2</i>		
Unpaired t test with Welch's correction	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - IMQ	ns	0.307
Figure 4E- Mac - <i>Il23p19</i>		
Unpaired t test	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} - IMQ vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre - IMQ	ns	0.4296

Figure 5

Figure 5B		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} -Veh vs <i>c-Jun</i> ^{fl/fl} -JNKi	***	0.0009
<i>c-Jun</i> ^{fl/fl} -Veh vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre	****	<0,0001
<i>c-Jun</i> ^{fl/fl} -Veh vs Tlr7 ^{-/-}	****	<0,0001
<i>c-Jun</i> ^{Δ/Δ} CD11c-Cre vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre-JNKi	ns	0.7688
Tlr7 ^{-/-} vs Tlr7 ^{-/-} - JNKi	ns	0.9997
Tlr7 ^{-/-} vs Tlr7 ^{-/-} <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre	ns	0.996
Figure 5C		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} -Veh vs <i>c-Jun</i> ^{fl/fl} -JNKi	****	<0,0001

c-Jun ^{fl/fl} -Veh vs c-Jun ^{Δ/Δ} CD11c-Cre	***	0.0003
c-Jun ^{fl/fl} -Veh vs Tlr7 ^{-/-}	**	0.004
c-Jun ^{Δ/Δ} CD11c-Cre vs c-Jun ^{Δ/Δ} CD11c-Cre-JNKi	ns	>0,9999
Tlr7 ^{-/-} vs Tlr7 ^{-/-} - JNKi	ns	0.9965
Tlr7 ^{-/-} vs Tlr7 ^{-/-} c-Jun ^{Δ/Δ} CD11c-Cre	ns	0.9996
Figure 5D		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
c-Jun ^{fl/fl} -Veh vs c-Jun ^{fl/fl} -JNKi	**	0.0022
c-Jun ^{fl/fl} -Veh vs c-Jun ^{Δ/Δ} CD11c-Cre	*	0.0363
c-Jun ^{fl/fl} -Veh vs Tlr7 ^{-/-}	**	0.0034
c-Jun ^{Δ/Δ} CD11c-Cre vs c-Jun ^{Δ/Δ} CD11c-Cre-JNKi	ns	0.9157
Tlr7 ^{-/-} vs Tlr7 ^{-/-} - JNKi	ns	>0,9999
Tlr7 ^{-/-} vs Tlr7 ^{-/-} c-Jun ^{Δ/Δ} CD11c-Cre	ns	>0,9999
Figure 5E		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
c-Jun ^{fl/fl} -Veh vs c-Jun ^{fl/fl} -JNKi	*	0.0122
c-Jun ^{fl/fl} -Veh vs c-Jun ^{Δ/Δ} CD11c-Cre	*	0.0144
c-Jun ^{fl/fl} -Veh vs Tlr7 ^{-/-}	**	0.0075
c-Jun ^{Δ/Δ} CD11c-Cre vs c-Jun ^{Δ/Δ} CD11c-Cre-JNKi	ns	0.6378
Tlr7 ^{-/-} vs Tlr7 ^{-/-} - JNKi	ns	0.6256
Tlr7 ^{-/-} vs Tlr7 ^{-/-} c-Jun ^{Δ/Δ} CD11c-Cre	ns	>0,9999
Figure 5F		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
c-Jun ^{fl/fl} -Veh vs c-Jun ^{fl/fl} -JNKi	*	0.0341

c-Jun ^{fl/fl} -Veh vs c-Jun ^{Δ/Δ} CD11c-Cre	*	0.0228
c-Jun ^{fl/fl} -Veh vs Tlr7 ^{-/-}	**	0.0073
c-Jun ^{Δ/Δ} CD11c-Cre vs c-Jun ^{Δ/Δ} CD11c-Cre-JNKi	ns	0.9975
Tlr7 ^{-/-} vs Tlr7 ^{-/-} - JNKi	ns	0.9962
Tlr7 ^{-/-} vs Tlr7 ^{-/-} c-Jun ^{Δ/Δ} CD11c-Cre	ns	>0,9999
Figure 5G		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
c-Jun ^{fl/fl} -Veh vs c-Jun ^{fl/fl} -JNKi	****	<0,0001
c-Jun ^{fl/fl} -Veh vs c-Jun ^{Δ/Δ} CD11c-Cre	****	<0,0001
c-Jun ^{fl/fl} -Veh vs Tlr7 ^{-/-}	***	0.0002
c-Jun ^{Δ/Δ} CD11c-Cre vs c-Jun ^{Δ/Δ} CD11c-Cre-JNKi	ns	0.9886
Tlr7 ^{-/-} vs Tlr7 ^{-/-} - JNKi	ns	0.9998
Tlr7 ^{-/-} vs Tlr7 ^{-/-} c-Jun ^{Δ/Δ} CD11c-Cre	ns	>0,999
Figure 5H		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
c-Jun ^{fl/fl} -Veh vs c-Jun ^{fl/fl} -JNKi	*	0.0151
c-Jun ^{fl/fl} -Veh vs c-Jun ^{Δ/Δ} CD11c-Cre	*	0.0189
c-Jun ^{fl/fl} -Veh vs Tlr7 ^{-/-}	*	0.0473
c-Jun ^{Δ/Δ} CD11c-Cre vs c-Jun ^{Δ/Δ} CD11c-Cre-JNKi	ns	0.8317
Tlr7 ^{-/-} vs Tlr7 ^{-/-} - JNKi	ns	>0,9999
Tlr7 ^{-/-} vs Tlr7 ^{-/-} c-Jun ^{Δ/Δ} CD11c-Cre	ns	>0,9999
Figure 5L		
Paired <i>t</i> test	Summary	<i>P</i> Value
<i>c-Jun/JunB</i> ^{Δ/Δ} <i>K5-Cre-ERT</i> ² Vehicle Day-14 vs Day-28	ns	0.0553

<i>c-Jun/JunB</i> ^{Δ/Δ} <i>K5-Cre-ER</i> ^{T2} JNKi Day-14 vs Day-28	*	0.0482
Figure 5N-Monocytes		
Bonferroni's multiple comparisons test	Summary	Adjusted P Value
<i>c-Jun/JunB</i> ^{Δ/Δ} <i>K5-Cre-ER</i> ^{T2} Vehicle vs JNKi	**	0.0034
Figure 5N-Neutrophils		
Bonferroni's multiple comparisons test	Summary	Adjusted P Value
<i>c-Jun/JunB</i> ^{Δ/Δ} <i>K5-Cre-ER</i> ^{T2} Vehicle vs JNKi	ns	>0,9999
Figure 5N-γδ TC		
Bonferroni's multiple comparisons test	Summary	Adjusted P Value
<i>c-Jun/JunB</i> ^{Δ/Δ} <i>K5-Cre-ER</i> ^{T2} Vehicle vs JNKi	*	0.0414

Figure 6

Figure 6C-CD1a		
Tukey's multiple comparisons test	Summary	Adjusted P Value
Healthy vs Non-Lesional	ns	0.7668
Healthy vs Lesional	***	0.0001
Non-Lesional vs Lesional	***	0.0007
Figure 6C-CD1c		
Tukey's multiple comparisons test	Summary	Adjusted P Value
Healthy vs Non-Lesional	ns	0.8962
Healthy vs Lesional	*	0.0193
Non-Lesional vs Lesional	ns	0.05
Figure 6C-CD14		
Tukey's multiple comparisons test	Summary	Adjusted P Value
Healthy vs Non-Lesional	ns	0.2896
Healthy vs Lesional	***	0.001
Non-Lesional vs Lesional	*	0.0333

Figure 7

Figure 7B - IL-23		
Paired t test	Summary	P Value
R-848 DMSO vs R848- JNKi	ns	0.058

Figure 7B - CCL2		
Paired t test	Summary	P Value
DMSO vs JNKi	ns	0.238
R-848 DMSO vs R848- JNKi	*	0.0309
Figure 7C- IL-23		
Paired t test	Summary	P Value
DMSO vs JNKi	ns	0.8837
R-848 DMSO vs R848- JNKi	*	0.013
Figure 7C- CCL2		
Paired t test	Summary	P Value
DMSO vs JNKi	ns	0.0501
R-848 DMSO vs R848- JNKi	**	0.0012
Figure 7E- CD80		
Paired t test	Summary	P Value
R-848 DMSO vs R848- JNKi	***	0.0006
R-848 DMSO vs R848- AP-1 Inh	ns	0.5004
Figure 7E- CD86		
Paired t test	Summary	P Value
R-848 DMSO vs R848- JNKi	**	0.0075
R-848 DMSO vs R848- AP-1 Inh.	ns	0.7325
Figure 7F-CCL2		
Paired t test	Summary	P Value
R-848 DMSO vs R848- JNKi	*	0.0161
R-848 DMSO vs R848- AP-1 Inh.	*	0.0342
Figure 7F- IL-23		
Paired t test	Summary	P Value
R-848 DMSO vs R848- JNKi	*	0.0154
R-848 DMSO vs R848- AP-1 Inh.	*	0.0138

EV Figure 1

Figure EV1E		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} 36h	***	0.0004
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} 48h	****	<0,0001
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre 72h	****	<0,0001
<i>c-Jun</i> ^{fl/fl} 36h vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre 36h	**	0.0011
<i>c-Jun</i> ^{fl/fl} 48h vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre 48h	***	0.0001
<i>c-Jun</i> ^{fl/fl} 72h vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre 72h	****	<0,0001
Figure EV1F		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} 36h	***	0.0004
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} 48h	****	<0,0001
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} 72h	***	0.0003
<i>c-Jun</i> ^{fl/fl} 36h vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre 36h	*	0.0322
<i>c-Jun</i> ^{fl/fl} 48h vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre 48h	****	<0,0001
Figure EV1G		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} 2 days	*	0.0491
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} 3 days	*	0.0438
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} 5 days	****	<0,0001
Figure EV1H		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} 5 days	ns	0.072

Figure EV1I		
Tukey's multiple comparisons test	Summary	Adjusted <i>P</i> Value
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} 2 days	*	0.0437
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} 3 days	**	0.009
<i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{fl/fl} 5 days	*	0.0101

EV Figure 2

Figure EV2B-Cxcl1		
Unpaired t test with Welch's correction	Summary	P Value
<i>c-Jun</i> ^{fl/fl} -32h vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre-32h *	ns	0.4137
<i>c-Jun</i> ^{fl/fl} -48h vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre-48h	***	0.001
Figure EV2B-Ccl20		
Unpaired t test	Summary	P Value
<i>c-Jun</i> ^{fl/fl} -32h vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre-32h *	ns	0.1655
<i>c-Jun</i> ^{fl/fl} -48h vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre-48h	*	0.0376
Figure EV2B-S100a8		
Unpaired t test with Welch's correction	Summary	P Value
<i>c-Jun</i> ^{fl/fl} -32h vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre-32h	ns	0.4487
<i>c-Jun</i> ^{fl/fl} -48h vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre-48h	**	0.0023
Figure EV2B-S100a9		
Unpaired t test with Welch's correction	Summary	P Value
<i>c-Jun</i> ^{fl/fl} -32h vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre-32h *	ns	0.6055
<i>c-Jun</i> ^{fl/fl} -48h vs <i>c-Jun</i> ^{Δ/Δ} CD11c-Cre-48h	ns	0.0766

Figure EV2B- <i>Il22</i>		
Unpaired t test with Welch's correction	Summary	P Value
c-Jun ^{fl/fl} -32h vs c-Jun ^{Δ/Δ} CD11c-Cre-32h *	ns	0.9803
c-Jun ^{fl/fl} -48h vs c-Jun ^{Δ/Δ} CD11c-Cre-48h	*	0.0102
Figure EV2B- <i>Il6</i>		
Unpaired t test with Welch's correction	Summary	P Value
c-Jun ^{fl/fl} -32h vs c-Jun ^{Δ/Δ} CD11c-Cre-32h *	ns	0.6252
c-Jun ^{fl/fl} -48h vs c-Jun ^{Δ/Δ} CD11c-Cre-48h	*	0.0142
Figure EV2B- <i>Tnfa</i>		
Unpaired t test	Summary	P Value
c-Jun ^{fl/fl} -32h vs c-Jun ^{Δ/Δ} CD11c-Cre-32h	ns	0.1399
c-Jun ^{fl/fl} -48h vs c-Jun ^{Δ/Δ} CD11c-Cre-48h	*	0.0275
Figure EV2B- <i>Il1b</i>		
Unpaired t test	Summary	P Value
c-Jun ^{fl/fl} -32h vs c-Jun ^{Δ/Δ} CD11c-Cre-32h	ns	0.7375
c-Jun ^{fl/fl} -48h vs c-Jun ^{Δ/Δ} CD11c-Cre-48h	ns	0.1058
Figure EV2C		
Unpaired t test with Welch's correction	Summary	P Value
c-Jun ^{fl/fl} - IMQ vs c-Jun ^{Δ/Δ} Mx1-Cre - IMQ - <i>Il22</i>	*	0.0439
Unpaired t test	Summary	P Value
c-Jun ^{fl/fl} - IMQ vs c-Jun ^{Δ/Δ} Mx1-Cre - IMQ - <i>Il23p19</i>	*	0.0145
c-Jun ^{fl/fl} - IMQ vs c-Jun ^{Δ/Δ} Mx1-Cre - IMQ - <i>Il6</i>	*	0.0155
c-Jun ^{fl/fl} - IMQ vs c-Jun ^{Δ/Δ} Mx1-Cre - IMQ - <i>Ccl20</i>	**	0.0025
c-Jun ^{fl/fl} - IMQ vs c-Jun ^{Δ/Δ} Mx1-Cre - IMQ - <i>Cxcl1</i>	*	0.0206
c-Jun ^{fl/fl} - IMQ vs c-Jun ^{Δ/Δ} Mx1-Cre - IMQ - <i>S100a8</i>	ns	0.7598
c-Jun ^{fl/fl} - IMQ vs c-Jun ^{Δ/Δ} Mx1-Cre - IMQ - <i>S100a9</i>	ns	0.638

c-Jun ^{fl/fl} - IMQ vs c-Jun ^{Δ/Δ} Mx1-Cre - IMQ - <i>Il1b</i>	ns	0.2366
c-Jun ^{fl/fl} - IMQ vs c-Jun ^{Δ/Δ} Mx1-Cre - IMQ - <i>Tnfa</i>	ns	0.135
Figure EV2F		
Unpaired t test	Summary	P Value
Wild-type- vs Wild-type - IMQ - CD45-	**	0.0047
Wild-type- vs Wild-type - IMQ - Gr-1	ns	0.2262
Figure EV2H		
Tukey's multiple comparisons test	Summary	Adjusted P Value
c-Jun ^{fl/fl} - LAL vs c-Jun ^{fl/fl} - IMQ	****	<0,0001
c-Jun ^{fl/fl} -IMQ vs c-Jun ^{Δ/Δ} Mx1-Cre - IMQ	ns	0.3345
Figure EV2I		
Tukey's multiple comparisons test	Summary	Adjusted P Value
IMQ vs IMQ-NF-κBi	***	0.0003

EV Figure 3

Figure EV3H		
Tukey's multiple comparisons test	Summary	Adjusted P Value
Wild-type mouse IgG1 vs JNKi	*	0.0269
Wild-type mouse IgG1 vs αIL23R	*	0.0245
Wild-type JNKi vs αIL23R	ns	0.9963
Figure EV3I-Monocytes		
Tukey's multiple comparisons test	Summary	Adjusted P Value
Wild-type mouse IgG1 vs JNKi	ns	0.0576
Wild-type mouse IgG1 vs αIL23R	ns	0.0576
Wild-type JNKi vs αIL23R	ns	>0,9999
Figure EV3I-Neutrophils		
Tukey's multiple comparisons test	Summary	Adjusted P Value
Wild-type mouse IgG1 vs JNKi	***	0.0006

Wild-type mouse IgG1 vs α L23R	**	0.0016
Wild-type JNKi vs α L23R	ns	0.4827
Figure EV3I-$\gamma\delta$ TC		
Tukey's multiple comparisons test	Summary	Adjusted P Value
Wild-type mouse IgG1 vs JNKi	ns	0.077
Wild-type mouse IgG1 vs α L23R	*	0.0311
Wild-type JNKi vs α L23R	ns	0.7504

EV Figure 5

FigureEV5B- CD80		
Paired t test	Summary	P Value
DMSO vs - JNKi	ns	0.0543
R-848 DMSO vs R848- JNKi	ns	0.0847
FigureEV5B- CD86		
Paired t test	Summary	P Value
DMSO vs - JNKi	ns	0.2091
R-848 DMSO vs R848- JNKi	ns	0.3187
FigureEV5D- CD80		
Paired t test	Summary	P Value
DMSO vs JNKi	ns	0.1275
R-848 DMSO vs R848- JNKi	ns	0.843
FigureEV5D- CD86		
Paired t test	Summary	P Value
DMSO vs JNKi	*	0.0448
R-848 DMSO vs R848- JNKi	ns	0.9272
FigureEV5F- CD80		
Tukey's multiple comparisons test	Summary	Adjusted P Value
Untreated vs LL-37-RNA-40	*	0.0104
Untreated vs RNA-40	ns	0.1643

Untreated vs LL-37	ns	0.2922
FigureEV5F- CD86		
Tukey's multiple comparisons test	Summary	Adjusted P Value
Untreated vs LL-37-RNA-40	**	0.0011
Untreated vs RNA-40	ns	0.5081
Untreated vs LL-37	ns	0.872
FigureEV5G- IL-23		
Tukey's multiple comparisons test	Summary	Adjusted P Value
Untreated vs LL-37-RNA-40	***	0.0002
Untreated vs RNA-40	ns	>0,9999
Untreated vs LL-37	ns	0.9998
FigureEV5G- CCL2		
Tukey's multiple comparisons test	Summary	Adjusted P Value
Untreated vs LL-37-RNA-40	**	0.0014
Untreated vs RNA-40	ns	0.9997
Untreated vs LL-37	ns	0.9997

Appendix Figure S2

Appendix Figure S2B		
Tukey's multiple comparisons test	Summary	Adjusted P Value
Wild-type-1.5 days vs CCL2 ^{-/-} - 1.5 days	ns	0.9937
Wild-type-3 days vs CCL2 ^{-/-} - 3 days	ns	>0,9999
Appendix Figure S2C- TEWL		
2 way - ANOVA	Summary	P Value
Wild-type- vs Ccl2 ^{-/-}	ns	0.7566
Appendix Figure S2E- Monocytes		
Unpaired <i>t</i> -test	Summary	P Value
Wild-type- IMQ vs Ccl2 ^{-/-} + IMQ	*	0.0123
Appendix Figure S2E- gd T cells		
Unpaired <i>t</i> -test	Summary	P Value
Wild-type- IMQ vs Ccl2 ^{-/-} + IMQ	ns	0.7771
Appendix Figure S2E- Macrophages		
Unpaired <i>t</i> -test	Summary	P Value
Wild-type- IMQ vs Ccl2 ^{-/-} + IMQ	**	0.0033
Appendix Figure S2E- Neutrophils		
Unpaired <i>t</i> -test	Summary	P Value
Wild-type- IMQ vs Ccl2 ^{-/-} + IMQ	ns	0.289

Appendix Figure S3

Appendix Figure S3A		
One way - ANOVA - Tukey	Summary	P Value
<i>Tlr7</i> ^{-/-} LAL vs <i>Tlr7</i> ^{-/-} AP-1 Inh.	*	0.0379
<i>Tlr7</i> ^{-/-} LAL vs <i>Tlr7</i> ^{-/-} AP-1 Inh. + IMQ	ns	0.0885
<i>c-Jun</i> ^{fl/fl} LAL vs <i>c-Jun</i> ^{fl/fl} AP-1 Inh.	***	0.0001
<i>c-Jun</i> ^{fl/fl} LAL vs <i>c-Jun</i> ^{fl/fl} + IMQ	**	0.0017
<i>c-Jun</i> ^{fl/fl} LAL vs <i>c-Jun</i> ^{fl/fl} AP-1 Inh. + IMQ	****	<0.0001
<i>c-Jun</i> ^{fl/fl} IMQ vs <i>c-Jun</i> ^{fl/fl} AP-1 Inh. + IMQ	*	0.0293
<i>c-Jun</i> ^{Δ/Δ} Mx1-Cre LAL vs AP-1 Inhibitor	*	0.0292
<i>c-Jun</i> ^{Δ/Δ} Mx1-Cre LAL vs AP-1 Inhibitor + IMQ	***	0.0005
Appendix Figure S3B		
One way - ANOVA - Tukey	Summary	P Value
<i>Tlr7</i> ^{-/-} LAL vs <i>Tlr7</i> ^{-/-} AP-1 Inh.	*	0.0452
<i>Tlr7</i> ^{-/-} LAL vs <i>Tlr7</i> ^{-/-} AP-1 Inh. + IMQ	ns	0.09
<i>c-Jun</i> ^{fl/fl} LAL vs <i>c-Jun</i> ^{fl/fl} AP-1 Inh.	**	0.0011
<i>c-Jun</i> ^{fl/fl} LAL vs <i>c-Jun</i> ^{fl/fl} + IMQ	ns	0.05
<i>c-Jun</i> ^{fl/fl} LAL vs <i>c-Jun</i> ^{fl/fl} AP-1 Inh. + IMQ	****	< 0.0001
<i>c-Jun</i> ^{Δ/Δ} Mx1-Cre LAL vs AP-1 Inhibitor + IMQ	**	0.0037
Appendix Figure S3C		
One way - ANOVA - Tukey	Summary	P Value
<i>c-Jun</i> ^{fl/fl} LAL vs <i>c-Jun</i> ^{fl/fl} + IMQ	****	< 0.0001
<i>c-Jun</i> ^{fl/fl} LAL vs <i>c-Jun</i> ^{fl/fl} AP-1 Inh. + IMQ	**	0.0011
<i>c-Jun</i> ^{fl/fl} IMQ vs <i>c-Jun</i> ^{fl/fl} AP-1 Inhibitor IMQ	****	< 0.0001

Appendix Figure S3D		
One way - ANOVA - Tukey	Summary	P Value
<i>c-Jun</i> ^{fl/fl} LAL vs <i>c-Jun</i> ^{fl/fl} + IMQ	****	< 0.0001
<i>c-Jun</i> ^{fl/fl} IMQ vs <i>c-Jun</i> ^{fl/fl} AP-1 Inh. + IMQ	****	< 0.0001
<i>c-Jun</i> ^{Δ/Δ} Mx1-Cre LAL vs IMQ	****	< 0.0001

Appendix Figure S4

Appendix Figure S4B		
One way - ANOVA Dunnett	Summary	P Value
<i>Il17a</i> : PBS vs 12h	**	0.0024
<i>Il17a</i> : PBS vs 36h	****	< 0.0001
<i>Ccl2</i> : PBS vs 12h	*	0.0318
Appendix Figure S4C		
Welch's t-test	Summary	P Value
<i>Il-12rb1</i> : LAL vs IMQ	*	0.0114
<i>Il-12rb2</i> : LAL vs IMQ	**	0.0049
Appendix Figure S4D		
One way - ANOVA - Tukey	Summary	P Value
<i>Gzmb</i> : LAL vs rIL-12	****	< 0.0001
<i>Trail</i> : LAL vs rIL-12	*	0.0276
<i>Ifng</i> : LAL vs rIL-12	*	0.0403

Appendix Figure S5

Appendix Figure S5A		
One way - ANOVA Tukey	Summary	P Value
<i>c-Jun</i> ^{fl/fl} LAL vs <i>c-Jun</i> ^{fl/fl} CL264	***	0.0001
<i>c-Jun</i> ^{fl/fl} LAL vs <i>c-Jun</i> ^{fl/fl} CL307	**	0.0018
<i>c-Jun</i> ^{Δ/Δ} Mx1-Cre LAL vs CL264	*	0.0261
<i>c-Jun</i> ^{Δ/Δ} Mx1-Cre LAL vs CL307	*	0.0441
Appendix Figure S5B		
One way - ANOVA Tukey	Summary	P Value
<i>c-Jun</i> ^{fl/fl} LAL vs <i>c-Jun</i> ^{fl/fl} CL264	*	0.0411
<i>c-Jun</i> ^{fl/fl} LAL vs <i>c-Jun</i> ^{fl/fl} CL307	**	0.0053

Appendix Figure S5C		
One way - ANOVA Tukey	Summary	P Value
<i>c-Jun</i> ^{fl/fl} LAL vs <i>c-Jun</i> ^{fl/fl} CL264	****	< 0.0001
<i>c-Jun</i> ^{fl/fl} LAL vs <i>c-Jun</i> ^{fl/fl} CL307	****	< 0.0001
CL264: <i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{Δ/Δ} Mx1-Cre	***	0.0002
CL307: <i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{Δ/Δ} Mx1-Cre	****	< 0.0001
Appendix Figure S5D		
One way - ANOVA Tukey	Summary	P Value
<i>c-Jun</i> ^{fl/fl} LAL vs <i>c-Jun</i> ^{fl/fl} CL264	****	< 0.0001
<i>c-Jun</i> ^{fl/fl} LAL vs <i>c-Jun</i> ^{fl/fl} CL307	****	< 0.0001
CL264: <i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{Δ/Δ} Mx1-Cre	**	0.0034
CL307: <i>c-Jun</i> ^{fl/fl} vs <i>c-Jun</i> ^{Δ/Δ} Mx1-Cre	***	0.0006
<i>c-Jun</i> ^{Δ/Δ} Mx1-Cre LAL vs CL264	****	< 0.0001
<i>c-Jun</i> ^{Δ/Δ} Mx1-Cre LAL vs CL307	****	< 0.0001

Appendix Figure S6

Appendix Figure S6B		
One way - ANOVA Tukey	Summary	P Value
<i>Gr-1⁺</i> vs. <i>CD45⁻</i>	*	0.0137
<i>Gr-1⁺</i> vs. <i>CD3ε⁺</i>	**	0.0097
<i>CD45⁻</i> vs. <i>CD3ε⁺</i>	ns	0.9998

Appendix Figure S7

Appendix Figure S7C		
One way - ANOVA Tukey	Summary	P Value
CCL2: IMQ-Vehicle vs IMQ- JNKi	**	0.0016
CXCL1: IMQ-Vehicle vs IMQ- JNKi	**	0.002
TNFα: IMQ-Vehicle vs IMQ- JNKi	ns	0.3157
TSLP: IMQ-Vehicle vs IMQ- JNKi	*	0.0118
IL-17A: IMQ-Vehicle vs IMQ- JNKi	****	<0,0001
IL-18: IMQ-Vehicle vs IMQ- JNKi	ns	0.128
IL-33: IMQ-Vehicle vs IMQ- JNKi	*	0.0485